PACB presents a deeply negative liquidation posture. Total assets of $782.4M are confronted by total liabilities of $780.0M, yielding book equity of only $2.4M. Under liquidation haircuts, the recovery to equity is materially negative. Cash and cash equivalents of $56.3M recover at 100%; short-term investments (AFS debt securities) of $219.7M recover near par. Accounts receivable of $29.4M recovers at 90-95%, approximately $26-28M. Inventory gross of $79.9M carries a $28.9M valuation reserve, leaving net inventory of $51.0M on the books; at a 60% liquidation recovery on net carrying value, that yields approximately $31M. PP&E net of $24.4M recovers at 50-70%, approximately $12-17M. Goodwill of $317.8M and finite-lived intangible assets net of $14.1M both recover at 0% under the liquidation lens. Total asset recovery approximates $360-380M under these assumptions. Against this, liabilities stand at face: convertible notes (2029 and 2030) aggregate $641M principal plus accrued carrying value of $644.1M on the balance sheet; operating lease liabilities total $59.3M noncurrent plus $0.3M current; deferred revenue (current $16.3M plus noncurrent $3.6M) must be serviced or refunded; accrued liabilities of $33.9M and accounts payable of $13.6M are at face. The liability stack substantially exceeds liquidation asset recovery, placing equity recovery deep in negative territory, consistent with MFFAIS CLV of negative $68.1M. Since the prior filing (FY2025 10-K, period ending December 31, 2025), the most significant structural change is the January 30, 2026 asset sale to Illumina Cambridge Limited of short-read DNA sequencing IP and related assets for $50M cash (recognized as GainLossOnDispositionOfAssets of $45.8M in Q1 FY2026). This transaction reduced the intangible asset base and generated a one-time cash inflow but did not materially alter the negative equity recovery posture. The retained liability disclosure for short-read technology obligations not assumed by Illumina represents an unquantified contingent claim. Operating cash burn of negative $44.7M in Q1 FY2026 compounds the deterioration. The Side Letter covenant with SBN restricting additional secured indebtedness to $75M constrains refinancing flexibility. Goodwill of $317.8M is the single largest balance sheet item and carries zero liquidation recovery; this concentration is the dominant driver of negative recovery. No goodwill impairment was recorded this quarter.
▼ Community Notes